# Lecture 12: Diabetes Mellitus - Pathophysiology ## Unit 2.3: Endocrine System --- ## Learning Objectives By the end of this lecture, students will be able to: 1. Describe the classification of diabetes mellitus 2. Explain the pathophysiology of type 1 diabetes mellitus 3. Describe the pathophysiology of type 2 diabetes mellitus 4. Explain insulin secretion, action, and resistance 5. Describe the metabolic consequences of insulin deficiency 6. Explain the pathophysiology of diabetic ketoacidosis and hyperosmolar state --- ## Lecture Outline ### I. Normal Glucose Homeostasis Maintaining blood glucose within a narrow physiologic range is essential for survival, as the brain depends on a continuous supply of glucose while other organs require protection from the damaging effects of chronic hyperglycemia. The body achieves this homeostasis through a tightly regulated interplay of glucose sources, hormonal signals, and tissue-specific metabolic responses that shift dynamically between fed and fasting states. The sources of circulating glucose vary depending on the metabolic state. In the fed or absorptive state, dietary carbohydrates serve as the primary source of blood glucose. During short-term fasting lasting approximately 4 to 16 hours, the liver maintains blood glucose through glycogenolysis, breaking down its stored glycogen reserves. In prolonged fasting, once glycogen stores are substantially depleted, gluconeogenesis in the liver and to a lesser extent the kidney becomes the dominant mechanism for generating glucose from non-carbohydrate precursors such as amino acids, lactate, and glycerol. This graduated transition ensures continuous glucose delivery to obligate glucose-consuming tissues, most notably the central nervous system. Several key hormones regulate blood glucose, with insulin serving as the sole glucose-lowering hormone and multiple counter-regulatory hormones acting to raise glucose levels. Insulin is secreted by pancreatic beta cells and is the body's primary anabolic and glucose-lowering signal. Glucagon, produced by pancreatic alpha cells, opposes insulin by stimulating hepatic glucose output. Epinephrine from the adrenal medulla raises glucose through glycogenolysis and lipolysis during stress responses. Cortisol from the adrenal cortex increases glucose through gluconeogenesis and peripheral insulin resistance. Growth hormone from the anterior pituitary similarly raises glucose by antagonizing insulin action and promoting lipolysis. The coordinated activity of these hormones ensures that blood glucose is maintained within the normal range across widely varying conditions of nutrient intake and energy expenditure. The actions of insulin on its target tissues are central to understanding diabetes pathophysiology. In the liver, insulin promotes glycogen synthesis while suppressing both gluconeogenesis and glycogenolysis, thereby reducing hepatic glucose output. In skeletal muscle, insulin stimulates glucose uptake through translocation of the GLUT4 transporter to the cell surface and enhances glycogen synthesis for energy storage. In adipose tissue, insulin promotes glucose uptake and lipogenesis while powerfully inhibiting lipolysis, keeping free fatty acids sequestered in adipocytes. As a general principle, insulin acts as the body's primary anabolic hormone, promoting the storage of glucose, fat, and protein when nutrient supply is abundant. The metabolic balance between the fed and fasting states is governed by the insulin-to-glucagon ratio. In the fed state, insulin levels are high and glucagon is low, driving anabolic processes and energy storage including glycogen synthesis, lipogenesis, and protein synthesis. In the fasting state, insulin levels fall and glucagon rises, shifting metabolism toward catabolic pathways and substrate mobilization including glycogenolysis, gluconeogenesis, lipolysis, and proteolysis. The dynamic interplay between these two hormones ensures that energy substrates are stored when available and mobilized when needed, and disruption of this balance forms the fundamental basis of diabetes mellitus. Panel A: Glucose sources by metabolic state showing dietary carbohydrates in fed state, hepatic glycogenolysis during short-term fasting (4-16 hours), and gluconeogenesis in liver and kidney during prolonged fasting. Panel B: Key hormone balance diagram showing insulin (decreases glucose, from beta cells) opposing counter-regulatory hormones glucagon (alpha cells), epinephrine (adrenal medulla), cortisol (adrenal cortex), and growth hormone (anterior pituitary). Panel C: Insulin tissue effects showing liver (increased glycogen synthesis, decreased gluconeogenesis), muscle (increased glucose uptake via GLUT4, increased glycogen synthesis), and adipose (increased glucose uptake, increased lipogenesis, decreased lipolysis). Panel D: Fed versus fasting state comparison showing fed state (high insulin, low glucagon, anabolic storage) versus fasting state (low insulin, high glucagon, catabolic mobilization) with metabolic flux arrows. --- ### II. Pancreatic Islet Physiology The islets of Langerhans are the endocrine microorgans of the pancreas responsible for glucose homeostasis. Understanding the cellular composition of islets, the process of insulin biosynthesis, and the mechanism of glucose-stimulated insulin secretion provides the foundation for comprehending how islet dysfunction leads to diabetes mellitus. The islets of Langerhans contain several distinct cell types, each producing a specific hormone. Beta cells are the most abundant, comprising 60-80% of islet cells, and are the sole source of insulin. Alpha cells make up 15-20% and produce glucagon, the primary counter-regulatory hormone to insulin. Delta cells account for 5-10% and secrete somatostatin, which exerts paracrine inhibitory effects on both insulin and glucagon release. PP cells constitute less than 5% and secrete pancreatic polypeptide, which modulates gastrointestinal function. Epsilon cells are the rarest at less than 1% and produce ghrelin, a hormone involved in appetite regulation. The close physical proximity of these cell types within the islet enables paracrine signaling that coordinates their hormonal output. Insulin biosynthesis is a multistep process beginning with transcription of the INS gene located on chromosome 11. Translation produces preproinsulin, which enters the endoplasmic reticulum where the signal peptide is cleaved to yield proinsulin. Within the Golgi apparatus and maturing secretory granules, proinsulin undergoes proteolytic cleavage to remove the connecting peptide (C-peptide), yielding the mature insulin molecule composed of an A chain and a B chain linked by disulfide bonds. Both insulin and C-peptide are stored together in secretory granules complexed with zinc and are released in equimolar amounts upon exocytosis. Because C-peptide is not extracted by the liver during first-pass metabolism, its measurement in plasma serves as a reliable indicator of endogenous insulin secretion. The mechanism of glucose-stimulated insulin secretion is a well-characterized sequence of events centered on metabolic sensing by the beta cell. Glucose enters the beta cell through the GLUT2 transporter, which has a high capacity and allows glucose entry proportional to the blood glucose concentration. Intracellular glucose is metabolized through glycolysis and mitochondrial oxidation, generating ATP. The rise in the ATP-to-ADP ratio causes closure of ATP-sensitive potassium channels (K_ATP channels) in the beta cell membrane, preventing potassium efflux and causing membrane depolarization. Depolarization activates voltage-gated calcium channels, producing an influx of calcium ions into the cytoplasm. The resulting increase in intracellular calcium triggers exocytosis of insulin-containing secretory granules. Insulin secretion in response to glucose follows a biphasic pattern: the first phase is rapid, occurring within minutes and reflecting release of a readily available pool of granules, while the second phase is more sustained and involves mobilization and release of a larger reserve pool. Beyond glucose, several other stimuli can promote insulin secretion. Amino acids, especially arginine and leucine, directly stimulate beta cells. The incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide), released from the gut in response to nutrient ingestion, potentiate glucose-stimulated insulin release, amplifying the secretory response to oral compared with intravenous glucose. Sulfonylurea drugs stimulate insulin secretion by directly closing K_ATP channels, bypassing the need for glucose metabolism. Vagal parasympathetic stimulation through acetylcholine also enhances insulin release, contributing to the cephalic phase of insulin secretion that occurs in anticipation of a meal. Panel A: Islet cell types showing beta cells (60-80%, insulin), alpha cells (15-20%, glucagon), delta cells (5-10%, somatostatin), PP cells (less than 5%, pancreatic polypeptide), and epsilon cells (less than 1%, ghrelin) in proportional arrangement. Panel B: Insulin synthesis pathway from INS gene on chromosome 11 through preproinsulin, signal peptide removal to proinsulin, C-peptide cleavage yielding mature insulin (A and B chains linked by disulfide bonds), and storage in secretory granules with zinc. Panel C: Glucose-stimulated insulin secretion mechanism showing glucose entry via GLUT2, ATP production from metabolism, K-ATP channel closure causing depolarization, calcium influx through voltage-gated channels, and exocytosis of insulin granules with biphasic release pattern. Panel D: Other insulin secretagogues showing amino acids (arginine, leucine), incretins (GLP-1 and GIP potentiating glucose-stimulated release), sulfonylureas (closing K-ATP channels), and vagal stimulation via acetylcholine. --- ### III. Diabetes Mellitus - Classification Diabetes mellitus is not a single disease but rather a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. A clear understanding of the classification system and diagnostic criteria is essential for appropriate clinical management, as the underlying pathophysiology differs substantially between types and guides therapeutic decisions. The major types of diabetes mellitus are distinguished by their underlying pathogenic mechanisms. Type 1 diabetes accounts for 5-10% of all cases and results from autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency. Type 2 diabetes is by far the most common form, comprising 90-95% of cases, and is characterized by the combination of insulin resistance in target tissues and progressive beta cell dysfunction. Gestational diabetes mellitus develops during pregnancy in women without pre-existing diabetes and reflects the insulin resistance of pregnancy exceeding the compensatory capacity of beta cells. Other specific types account for less than 5% of cases and include monogenic forms of diabetes as well as diabetes secondary to other conditions. The category of other specific types encompasses a diverse group of conditions. Monogenic diabetes, also known as maturity-onset diabetes of the young (MODY), results from single-gene mutations affecting beta cell function, with the most common forms caused by mutations in HNF1A, HNF4A, and GCK genes. Pancreatic diseases that destroy or impair islet function can cause diabetes, including chronic pancreatitis, cystic fibrosis, and hemochromatosis with iron deposition in the pancreas. Endocrinopathies associated with excess counter-regulatory hormones can induce diabetes, including Cushing syndrome (cortisol excess), acromegaly (growth hormone excess), and pheochromocytoma (catecholamine excess). Drug-induced diabetes occurs with medications that impair insulin secretion or action, notably glucocorticoids, thiazide diuretics, and atypical antipsychotics. Certain genetic syndromes including Down syndrome, Klinefelter syndrome, and Turner syndrome are associated with increased diabetes risk through various mechanisms. The diagnostic criteria for diabetes mellitus provide standardized thresholds for establishing the diagnosis. A fasting plasma glucose of 126 mg/dL or greater meets the diagnostic threshold for diabetes, while values of 100-125 mg/dL define impaired fasting glucose (IFG), a prediabetic state. A 2-hour plasma glucose of 200 mg/dL or greater during a 75-gram oral glucose tolerance test (OGTT) is diagnostic, with values of 140-199 mg/dL defining impaired glucose tolerance (IGT). A hemoglobin A1c (HbA1c) of 6.5% or greater is diagnostic of diabetes, while values of 5.7-6.4% indicate prediabetes. A random plasma glucose of 200 mg/dL or greater in the presence of classic hyperglycemic symptoms is also diagnostic. Importantly, in the absence of unequivocal hyperglycemia with acute metabolic decompensation, the diagnosis requires confirmation with two abnormal tests, which may be the same test repeated or two different tests. Panel A: Diabetes types showing type 1 (5-10%, autoimmune beta cell destruction), type 2 (90-95%, insulin resistance plus beta cell dysfunction), gestational (pregnancy-induced), and other specific types (less than 5%, monogenic and secondary). Panel B: Other specific diabetes types including monogenic MODY (HNF1A, HNF4A, GCK mutations), pancreatic disease (pancreatitis, cystic fibrosis), endocrinopathies (Cushing, acromegaly), drug-induced (glucocorticoids, thiazides), and genetic syndromes. Panel C: Diagnostic criteria table showing fasting glucose (126 mg/dL or greater for diabetes, 100-125 for IFG), 2-hour OGTT (200 or greater, 140-199 for IGT), HbA1c (6.5% or greater, 5.7-6.4% for prediabetes), and random glucose (200 or greater with symptoms). Panel D: Prediabetes spectrum showing impaired fasting glucose and impaired glucose tolerance as intermediate states between normal and diabetes, with two abnormal tests required for confirmation. --- ### IV. Type 1 Diabetes Mellitus Type 1 diabetes mellitus results from autoimmune destruction of the insulin-producing beta cells of the pancreas, ultimately leading to absolute insulin deficiency and lifelong dependence on exogenous insulin. The disease arises through the interplay of genetic susceptibility, environmental triggers, and immune dysregulation, progressing through identifiable preclinical stages before manifesting as overt clinical diabetes. The epidemiology of type 1 diabetes reveals characteristic patterns. The disease typically presents before age 30, with two peak periods of incidence at ages 4-6 and 10-14 years. The annual incidence is approximately 15-30 per 100,000, with significant geographic variation showing higher rates in Northern Europe and Sardinia. Notably, the incidence of type 1 diabetes has been increasing worldwide, a trend that suggests the growing influence of environmental factors given the stability of the genetic pool over such short time frames. The pathophysiology of type 1 diabetes centers on autoimmune destruction of pancreatic beta cells. The process is mediated primarily by autoreactive T lymphocytes that infiltrate the islets, producing a histologic pattern known as insulitis. This destructive process unfolds over years of subclinical beta cell loss, during which the remaining beta cells compensate by increasing their insulin output. Clinical symptoms typically do not appear until approximately 90% of beta cell mass has been destroyed, at which point the residual cells can no longer maintain euglycemia. The end result is absolute insulin deficiency, distinguishing type 1 fundamentally from type 2 diabetes, where insulin resistance predominates and some endogenous insulin production persists. Genetic susceptibility plays a major role in type 1 diabetes, though the disease is not purely genetic. The strongest genetic association is with the HLA class II genes, particularly HLA-DR3 and HLA-DR4, which are present in the majority of affected individuals. HLA-DQ alleles are also associated with susceptibility or protection. HLA class II molecules present autoantigens to T helper cells, and specific allelic variants alter the efficiency of this process. Despite the strong genetic component, the concordance rate in identical twins is only approximately 50%, indicating that environmental factors are necessary to trigger the autoimmune process. The risk of developing type 1 diabetes is approximately 5-6% if a sibling is affected, substantially higher than the general population risk but still relatively low, reflecting the complex polygenic nature of susceptibility. Several autoantibodies serve as serologic markers of the autoimmune process and are used clinically to confirm the diagnosis and predict disease development in at-risk individuals. Antibodies to glutamic acid decarboxylase (GAD65) are present in 70-80% of patients at diagnosis and are the most commonly used marker. Antibodies to islet antigen 2 (IA-2) have approximately 60% sensitivity. Insulin autoantibodies (IAA) are detected more commonly in young children. Antibodies to the zinc transporter ZnT8 are found in 60-80% of patients. The presence of multiple autoantibodies is highly predictive of progression to clinical diabetes, and these markers are used both to confirm autoimmune etiology in individual patients and to identify at-risk relatives for potential prevention trials. Environmental triggers are believed to initiate or accelerate the autoimmune process in genetically susceptible individuals. Viral infections have the strongest evidence as precipitants, with Coxsackie B virus, enteroviruses, and congenital rubella all implicated through molecular mimicry or direct beta cell damage. Dietary factors such as early exposure to cow's milk protein have been proposed as triggers, though evidence remains controversial. The hygiene hypothesis suggests that decreased exposure to infections in developed countries leads to immune dysregulation and increased autoimmunity, potentially explaining the rising incidence. Vitamin D deficiency has been identified as a possible contributing factor based on epidemiologic associations. The natural history of type 1 diabetes has been formalized into three stages: stage 1 is defined by the presence of two or more autoantibodies with normoglycemia, representing the earliest identifiable preclinical phase; stage 2 is characterized by two or more autoantibodies with dysglycemia, indicating progressive beta cell loss; and stage 3 is clinical diabetes with symptomatic hyperglycemia. This staging framework enables earlier identification of at-risk individuals and provides a structure for prevention research. Panel A: Autoimmune pathophysiology showing T lymphocyte-mediated insulitis destroying beta cells over years of subclinical destruction, with clinical symptoms appearing when approximately 90% of beta cells are destroyed resulting in absolute insulin deficiency. Panel B: Genetic factors showing HLA-DR3/DR4 as the strongest genetic association, HLA-DQ also associated, 5-6% sibling risk, and approximately 50% concordance in identical twins, with HLA class II conferring susceptibility or protection. Panel C: Autoantibodies showing GAD65 (70-80% sensitivity), IA-2 (60%), IAA (more common in children), and ZnT8 (60-80%) used clinically to confirm type 1 and predict development in relatives, with environmental triggers including Coxsackie B virus, enterovirus, and dietary factors. Panel D: Natural history staging showing stage 1 (2 or more autoantibodies with normoglycemia), stage 2 (2 or more autoantibodies with dysglycemia), and stage 3 (clinical diabetes) as progressive beta cell loss with declining beta cell mass plotted over time. --- ### V. Type 2 Diabetes Mellitus Type 2 diabetes mellitus is the most common form of diabetes, accounting for the vast majority of cases worldwide. Unlike type 1, which results from autoimmune beta cell destruction, type 2 arises from the combination of insulin resistance in target tissues and a progressive failure of beta cells to compensate for that resistance. Understanding the multiple pathophysiologic defects that contribute to type 2 diabetes has led to a more comprehensive therapeutic approach targeting distinct mechanisms. The epidemiology of type 2 diabetes reflects its strong association with obesity and lifestyle factors. The disease has traditionally presented in adults over age 40, although it is increasingly diagnosed in younger individuals and even adolescents, paralleling the rising prevalence of childhood obesity. Approximately 10% of adults in the United States are affected. Major risk factors include obesity (particularly visceral adiposity), sedentary lifestyle, and family history, with the disease showing significantly higher prevalence in certain ethnic populations including African American, Hispanic, Native American, and South Asian groups. The pathophysiology of type 2 diabetes involves multiple simultaneous defects, conceptualized by DeFronzo as the "ominous octet" to emphasize the complexity of the disease. Decreased insulin secretion from beta cell dysfunction is a central defect that worsens progressively over time. Increased glucagon secretion from alpha cell excess contributes to fasting and postprandial hyperglycemia by driving hepatic glucose production. Increased hepatic glucose output results from decreased insulin-mediated suppression of gluconeogenesis and glycogenolysis. Insulin resistance in skeletal muscle reduces glucose uptake, which is quantitatively the most important site of insulin-stimulated glucose disposal. Insulin resistance in adipose tissue leads to increased lipolysis and elevated circulating free fatty acids, which further worsen hepatic and muscle insulin resistance. A decreased incretin effect, reflecting either resistance to or deficiency of GLP-1, reduces the gut-derived amplification of insulin secretion. Increased renal glucose reabsorption through SGLT2 activity raises the renal threshold for glucose excretion, maintaining hyperglycemia. Brain insulin resistance alters satiety signaling and contributes to increased caloric intake and obesity. Insulin resistance, the hallmark of type 2 diabetes, is defined as a decreased tissue response to normal circulating insulin concentrations. The primary sites of insulin resistance are skeletal muscle, liver, and adipose tissue, each contributing distinct metabolic consequences. At the molecular level, insulin resistance involves post-receptor signaling defects rather than abnormalities in the insulin receptor itself. Several mechanisms drive these defects. Lipotoxicity occurs when excess free fatty acids are converted to diacylglycerol, which activates protein kinase C (PKC), leading to serine phosphorylation and impairment of insulin receptor substrate-1 (IRS-1). Chronic low-grade inflammation, characterized by elevated levels of TNF-alpha and IL-6 from visceral adipose tissue, promotes serine phosphorylation of IRS proteins, interfering with normal insulin signal transduction. Endoplasmic reticulum stress activates the unfolded protein response, which impairs insulin signaling pathways. Mitochondrial dysfunction reduces oxidative capacity, leading to accumulation of lipid intermediates. Ectopic fat deposition in liver and skeletal muscle directly impairs insulin action in these tissues. Initially, the pancreatic beta cells compensate for insulin resistance by increasing insulin secretion, maintaining normal glucose levels through hyperinsulinemia. Over time, however, beta cells fail to sustain this compensatory output, and decompensation occurs as glucose levels rise. Beta cell dysfunction in type 2 diabetes is progressive and ultimately determines the clinical trajectory. The earliest detectable defect is loss of the first-phase insulin secretory response to glucose, which is critical for suppressing hepatic glucose output after meals. As the disease progresses, beta cell mass declines through apoptosis, driven in part by the deposition of islet amyloid polypeptide (IAPP, or amylin), which forms toxic oligomers within the islets. Glucotoxicity, the phenomenon whereby chronic hyperglycemia itself impairs beta cell function and insulin gene expression, creates a vicious cycle of worsening hyperglycemia and further beta cell deterioration. Similarly, lipotoxicity from elevated free fatty acids damages beta cells through oxidative stress and endoplasmic reticulum stress. The inexorable decline in beta cell function over time explains why many patients with type 2 diabetes eventually require insulin therapy despite initially responding to oral agents. The risk factors for type 2 diabetes span both non-modifiable and modifiable categories. Non-modifiable risk factors include advancing age, family history of diabetes, ethnicity, and a history of gestational diabetes. Modifiable risk factors include obesity (especially visceral or central adiposity), sedentary lifestyle, and dietary patterns high in refined carbohydrates and saturated fats. Metabolic risk factors that identify individuals at highest risk include prediabetes (impaired fasting glucose or impaired glucose tolerance), metabolic syndrome, and polycystic ovary syndrome (PCOS), each of which is associated with underlying insulin resistance. Panel A: The ominous octet showing eight pathophysiologic defects: decreased insulin secretion (beta cell dysfunction), increased glucagon (alpha cell excess), increased hepatic glucose output, muscle insulin resistance, adipose insulin resistance (increased lipolysis), decreased incretin effect, increased renal glucose reabsorption (SGLT2), and brain insulin resistance (altered satiety). Panel B: Insulin resistance molecular mechanisms showing lipotoxicity (FFA to diacylglycerol to PKC to decreased IRS-1), inflammation (TNF-alpha, IL-6 causing serine phosphorylation of IRS), ER stress, mitochondrial dysfunction, and ectopic fat deposition in liver and muscle. Panel C: Beta cell dysfunction progression showing loss of first-phase insulin secretion as earliest defect, decreased beta cell mass from apoptosis and amyloid (IAPP) deposition, glucotoxicity and lipotoxicity worsening function, with progressive decline over time from initial compensation to decompensation. Panel D: Risk factors showing non-modifiable (age, family history, ethnicity, gestational diabetes history) and modifiable (obesity especially visceral, sedentary lifestyle, diet) with metabolic risk factors (prediabetes, metabolic syndrome, PCOS). --- ### VI. Insulin Signaling The molecular mechanisms by which insulin exerts its metabolic effects involve a well-characterized signaling cascade from receptor binding to downstream metabolic responses. Understanding this pathway explains both the normal actions of insulin and the specific points at which signaling is disrupted in insulin-resistant states, providing a rational basis for therapeutic intervention. The insulin receptor is a receptor tyrosine kinase with an alpha-2-beta-2 heterotetramer structure. The two alpha subunits are located entirely extracellularly and contain the insulin-binding domains. The two beta subunits span the cell membrane and possess intrinsic tyrosine kinase activity in their cytoplasmic domains. When insulin binds to the alpha subunits, a conformational change activates the tyrosine kinase activity of the beta subunits, initiating the intracellular signaling cascade. This receptor structure is found on virtually all mammalian cell types, though its density varies, being particularly high on hepatocytes, adipocytes, and skeletal muscle cells. The insulin signaling cascade proceeds through a series of phosphorylation events. Upon insulin binding, the beta subunits undergo autophosphorylation on specific tyrosine residues, creating docking sites for downstream signaling molecules. Insulin receptor substrates 1 and 2 (IRS-1 and IRS-2) are recruited and phosphorylated on tyrosine residues by the activated receptor. Tyrosine-phosphorylated IRS proteins activate phosphoinositide 3-kinase (PI3K), which generates phosphatidylinositol-3,4,5-trisphosphate (PIP3) in the cell membrane. PIP3 recruits and activates the serine/threonine kinase Akt (also known as protein kinase B), which is the central node for most of insulin's metabolic effects. Akt activation leads to translocation of GLUT4 glucose transporters from intracellular vesicular stores to the plasma membrane, enabling insulin-stimulated glucose uptake, along with additional metabolic effects on glycogen synthesis, lipogenesis, and protein synthesis. The family of facilitative glucose transporters (GLUTs) demonstrates tissue-specific expression that has important implications for glucose metabolism in health and diabetes. GLUT1 is ubiquitously expressed, found at particularly high levels in red blood cells and at the blood-brain barrier, and is insulin-independent, ensuring constitutive glucose supply to these tissues. GLUT2 is expressed in the liver, pancreatic beta cells, and intestinal epithelium; its high capacity and low affinity allow it to function as a glucose sensor in beta cells and to mediate bidirectional glucose transport in the liver. GLUT3 is the predominant neuronal glucose transporter, insulin-independent and with high affinity to ensure reliable glucose supply to the brain. GLUT4 is the uniquely insulin-responsive transporter found in skeletal muscle and adipose tissue; it is stored in intracellular vesicles and translocated to the cell surface only in response to insulin signaling, making it the molecular effector of insulin-stimulated glucose uptake. GLUT5 is found in the intestinal brush border and mediates fructose absorption. The insulin dependence of GLUT4 explains why skeletal muscle and adipose tissue are the primary sites where glucose uptake is impaired in insulin-resistant states. The downstream metabolic effects of insulin signaling through the Akt pathway are diverse and collectively promote anabolic metabolism. GLUT4 translocation to the plasma membrane increases glucose uptake into muscle and adipose tissue. Glycogen synthase is activated, promoting glycogen storage in liver and muscle. Acetyl-CoA carboxylase is stimulated, enhancing lipogenesis and fatty acid synthesis. The mTOR pathway is activated, increasing protein synthesis and cellular growth. Simultaneously, insulin suppresses catabolic pathways: gluconeogenic enzymes phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) are downregulated, reducing hepatic glucose production, and hormone-sensitive lipase is inhibited, suppressing lipolysis in adipose tissue. This coordinated activation of anabolic pathways and suppression of catabolic pathways establishes insulin as the master regulator of fuel storage and utilization. Panel A: Insulin receptor structure showing receptor tyrosine kinase with alpha-2-beta-2 heterotetramer configuration, extracellular alpha subunits for insulin binding, and transmembrane beta subunits with intracellular kinase activity. Panel B: Signaling cascade showing insulin binding to alpha subunit, beta subunit autophosphorylation, IRS-1/2 phosphorylation, PI3K activation, and Akt activation leading to metabolic effects. Panel C: GLUT transporter family showing GLUT1 (ubiquitous, insulin-independent), GLUT2 (liver and beta cells, insulin-independent), GLUT3 (neurons, insulin-independent), GLUT4 (muscle and adipose, insulin-dependent, stored intracellularly), and GLUT5 (intestine, fructose). Panel D: Downstream insulin effects showing GLUT4 translocation for glucose uptake, increased glycogen synthase activity, increased lipogenesis via acetyl-CoA carboxylase, increased protein synthesis via mTOR, and decreased gluconeogenesis (PEPCK, G6Pase) and lipolysis (hormone-sensitive lipase). --- ### VII. Metabolic Consequences of Insulin Deficiency When insulin is absent or its action is severely impaired, the metabolic consequences affect carbohydrate, lipid, and protein metabolism simultaneously. The body enters a catabolic state in which glucose accumulates in the blood while tissues are starved for fuel, fat stores are mobilized producing potentially dangerous ketone bodies, and muscle protein is broken down to provide substrates for gluconeogenesis. These metabolic derangements produce the classic symptoms of uncontrolled diabetes. The effects on carbohydrate metabolism are the most immediately apparent consequence of insulin deficiency. Hyperglycemia develops through two complementary mechanisms: decreased peripheral glucose uptake by insulin-dependent tissues (primarily skeletal muscle and adipose via GLUT4) and simultaneously increased hepatic glucose production through unrestrained gluconeogenesis and glycogenolysis. When the blood glucose concentration exceeds the renal threshold for glucose reabsorption, approximately 180 mg/dL, glucose spills into the urine (glycosuria). The presence of glucose in the renal tubular fluid creates an osmotic gradient that opposes water reabsorption, producing osmotic diuresis with large volumes of dilute urine (polyuria). The resulting dehydration and increased plasma osmolality trigger the thirst mechanism, causing polydipsia as the body attempts to replace lost fluid. The effects on lipid metabolism are particularly important because they drive the development of diabetic ketoacidosis. In the absence of insulin's tonic inhibition of hormone-sensitive lipase, lipolysis in adipose tissue accelerates dramatically, releasing large quantities of free fatty acids into the circulation. The liver, stimulated by glucagon and uninhibited by insulin, takes up these free fatty acids and diverts them into beta-oxidation rather than re-esterification. Beta-oxidation of fatty acids in hepatic mitochondria generates acetyl-CoA in excess of the capacity of the citric acid cycle, and this surplus acetyl-CoA is shunted into ketogenesis, producing the ketone bodies beta-hydroxybutyrate, acetoacetate, and acetone. Additionally, insulin deficiency promotes increased hepatic production of very-low-density lipoprotein (VLDL), resulting in hyperlipidemia with elevated triglycerides. The effects on protein metabolism contribute to the muscle wasting and weight loss characteristic of uncontrolled diabetes. Without insulin's anabolic drive, proteolysis in skeletal muscle increases, releasing amino acids into the circulation. These amino acids serve as substrates for hepatic gluconeogenesis, further worsening hyperglycemia. The combination of muscle protein breakdown and fat catabolism produces significant weight loss, even in the face of increased caloric intake. The nitrogen balance becomes negative, as protein catabolism exceeds synthesis, reflecting the overall shift from anabolism to catabolism. The classic clinical presentation of uncontrolled diabetes is summarized by the "three Ps" plus weight loss. Polyuria results from osmotic diuresis caused by glycosuria. Polydipsia represents compensatory thirst in response to the dehydration produced by osmotic diuresis. Polyphagia occurs because cells are unable to take up and utilize glucose effectively despite its abundance in the blood, creating a state of cellular starvation that stimulates appetite. Weight loss results from the catabolism of fat stores and muscle protein, as the body breaks down its own tissues for fuel in the absence of insulin-mediated glucose utilization. This combination of symptoms, particularly when rapid in onset, should prompt immediate consideration of diabetes and especially type 1 diabetes in a previously undiagnosed patient. Panel A: Carbohydrate metabolism effects showing hyperglycemia from decreased glucose uptake and increased gluconeogenesis, glycosuria exceeding renal threshold (approximately 180 mg/dL), osmotic diuresis from glucose in urine pulling water, and polyuria with polydipsia. Panel B: Lipid metabolism effects showing increased lipolysis from loss of insulin inhibition, elevated free fatty acids, hepatic ketogenesis via beta-oxidation producing ketone bodies, and hyperlipidemia from increased VLDL production. Panel C: Protein metabolism effects showing increased proteolysis and muscle breakdown, elevated amino acids serving as gluconeogenesis substrates, muscle wasting causing weight loss despite polyphagia, and negative nitrogen balance. Panel D: Classic 3P symptoms plus weight loss showing polyuria (osmotic diuresis), polydipsia (compensatory thirst), polyphagia (cellular starvation as glucose cannot enter cells), and weight loss (fat and protein catabolism) as the hallmark presentation. --- ### VIII. Diabetic Ketoacidosis (DKA) Diabetic ketoacidosis is a life-threatening metabolic emergency characterized by the triad of hyperglycemia, ketonemia, and metabolic acidosis. It results from absolute or severe relative insulin deficiency combined with an excess of counter-regulatory hormones, most commonly occurring in type 1 diabetes but also possible in type 2 under conditions of severe physiologic stress. Understanding the pathophysiology of DKA explains its clinical presentation and guides rational treatment. The pathophysiology of DKA involves the combined effects of insulin deficiency and counter-regulatory hormone excess. The insulin deficiency may be absolute, as in type 1 diabetes, or relative, as when physiologic stress overwhelms available insulin. Simultaneously, levels of counter-regulatory hormones, including glucagon, cortisol, epinephrine, and growth hormone, rise markedly. Glucagon is particularly important, as it drives hepatic glucose production and promotes ketogenesis. The profound insulin deficiency unleashes lipolysis, releasing massive quantities of free fatty acids from adipose tissue. The liver, stimulated by the high glucagon-to-insulin ratio, converts these free fatty acids into ketone bodies through beta-oxidation and ketogenesis. The three ketone bodies produced are beta-hydroxybutyrate (the predominant ketone in DKA), acetoacetate, and acetone. Beta-hydroxybutyrate and acetoacetate are strong organic acids that dissociate at physiologic pH, consuming bicarbonate buffer and producing a high-anion-gap metabolic acidosis. Several precipitating factors can trigger DKA, and identifying the precipitant is essential for successful management. Infection is the most common trigger, as the physiologic stress of infection raises counter-regulatory hormones while increasing insulin requirements. Insulin omission, whether through non-compliance with prescribed therapy or failure of an insulin pump, is the second most common cause. New-onset type 1 diabetes frequently presents with DKA as the initial manifestation. Major physiologic stresses such as myocardial infarction or stroke can precipitate DKA through the associated stress hormone response. Certain medications can trigger DKA, including glucocorticoids (which raise glucose and increase insulin resistance) and, notably, SGLT2 inhibitors, which can cause a form of DKA termed euglycemic DKA, where ketoacidosis occurs with only mildly elevated or even normal blood glucose levels. The laboratory findings in DKA reflect the underlying metabolic derangements. Blood glucose is usually greater than 250 mg/dL, though it may be lower in euglycemic DKA. The arterial pH falls below 7.3, and serum bicarbonate drops below 18 mEq/L, reflecting the metabolic acidosis. The anion gap is elevated above 12, calculated as sodium minus (chloride plus bicarbonate), due to the accumulation of unmeasured ketoacid anions. Serum ketones are positive, with serum beta-hydroxybutyrate being the preferred measurement as it is the predominant ketone in DKA and is not detected by the traditional nitroprusside urine ketone test. Serum potassium is often initially elevated despite total body potassium depletion, because acidosis causes a transcellular shift of potassium out of cells in exchange for hydrogen ions. Osmolality is variable, depending on the degree of hyperglycemia and dehydration. The clinical features of DKA reflect dehydration, acidosis, and the ketotic state. Dehydration is typically profound, resulting from osmotic diuresis, vomiting, and decreased oral intake. Kussmaul breathing, characterized by deep and rapid respirations, represents respiratory compensation for metabolic acidosis as the lungs attempt to blow off carbon dioxide. The fruity or acetone odor of the breath results from volatile acetone exhaled through the lungs. Nausea and vomiting are common and contribute to dehydration and electrolyte depletion. Abdominal pain can be severe and may mimic an acute abdomen, sometimes leading to unnecessary surgical consultation; the mechanism is thought to involve gastric distention and peritoneal irritation from acidosis. Altered mental status, ranging from lethargy to coma, occurs in severe cases and correlates with the degree of hyperosmolality and acidosis. Panel A: DKA pathophysiology showing absolute insulin deficiency (type 1) or relative deficiency combined with counter-regulatory hormone excess (glucagon, cortisol, epinephrine, growth hormone) driving metabolic derangement. Panel B: Ketone production pathway showing insulin deficiency causing increased lipolysis, markedly elevated free fatty acids, hepatic conversion to ketone bodies (beta-hydroxybutyrate, acetoacetate, acetone) via beta-oxidation, resulting in metabolic acidosis. Panel C: Precipitating factors showing infection (most common trigger), insulin omission or pump failure, new type 1 diabetes diagnosis, MI or stroke (stress response), and drugs (glucocorticoids, SGLT2 inhibitors). Panel D: Laboratory findings and clinical features showing glucose usually greater than 250 mg/dL, pH less than 7.3, bicarbonate less than 18, elevated anion gap, positive ketones, with Kussmaul breathing, fruity breath (acetone), abdominal pain, and altered mental status. --- ### IX. Hyperosmolar Hyperglycemic State (HHS) Hyperosmolar hyperglycemic state is the other major acute metabolic complication of diabetes, distinguished from DKA by extreme hyperglycemia, profound dehydration, and hyperosmolarity in the relative absence of significant ketoacidosis. HHS occurs predominantly in type 2 diabetes and carries a substantially higher mortality rate than DKA, largely because it tends to affect older patients with comorbidities and develops insidiously over days to weeks before recognition. The pathophysiology of HHS centers on a critical distinction from DKA: the presence of sufficient endogenous insulin to prevent ketogenesis but insufficient insulin to prevent hyperglycemia. In type 2 diabetes, even severely insulin-resistant patients typically maintain enough residual insulin secretion to suppress lipolysis and ketogenesis in adipose tissue, but not enough to promote adequate peripheral glucose uptake or suppress hepatic glucose output. As a result, blood glucose rises to extreme levels, often exceeding 600 mg/dL and sometimes surpassing 1000 mg/dL. This severe hyperglycemia drives massive osmotic diuresis, producing fluid losses that can exceed those seen in DKA. The resulting hyperosmolarity, with serum osmolality typically exceeding 320 mOsm/kg, causes water to shift out of neurons, producing the characteristic neurologic manifestations. Dehydration in HHS is generally more profound than in DKA because the absence of ketoacidosis symptoms means patients do not seek medical attention as quickly, allowing the osmotic diuresis to continue unopposed for a longer period. The comparison between HHS and DKA highlights important clinical distinctions that guide diagnosis and management. HHS typically occurs in type 2 diabetes while DKA occurs predominantly in type 1. Blood glucose in HHS is markedly higher, usually exceeding 600 mg/dL compared to typically above 250 mg/dL in DKA. Serum osmolality is substantially elevated in HHS above 320 mOsm/kg while it is variable in DKA. Ketones are minimal or absent in HHS but significantly elevated in DKA. The pH remains above 7.3 in HHS while falling below 7.3 in DKA. Dehydration is severe in HHS, while moderate to severe in DKA. Altered mental status is common and often prominent in HHS, correlating with the degree of hyperosmolarity, while it is variable in DKA. The mortality rate of HHS is considerably higher at approximately 10-20% compared to 1-5% for DKA, reflecting both the older patient population and the severity of the metabolic derangement. The clinical features of HHS develop insidiously and reflect the profound dehydration and hyperosmolarity. Dehydration is typically extreme, with fluid deficits often reaching 8-12 liters by the time of presentation. Altered mental status is the hallmark neurologic manifestation and correlates with the degree of serum osmolality elevation, ranging from confusion to obtundation to coma. Focal neurologic signs including hemiparesis and hemisensory loss may be present and can mimic acute stroke, making it essential to check glucose in any patient presenting with focal neurologic deficits. Seizures may occur as a result of the hyperosmolar state. Importantly, Kussmaul breathing is absent because there is no significant metabolic acidosis, distinguishing the clinical presentation from DKA. The precipitants of HHS overlap with those of DKA but tend to be particularly associated with conditions that impair fluid intake. Infections, particularly pneumonia and urinary tract infections, are the most common triggers. Medications including diuretics (which worsen dehydration) and glucocorticoids (which worsen hyperglycemia) can precipitate HHS. Non-compliance with diabetes medications or an undiagnosed case of type 2 diabetes may underlie the presentation. Other acute illnesses including myocardial infarction and stroke can trigger HHS through the stress hormone response. Elderly patients and nursing home residents are particularly vulnerable because they may have impaired thirst mechanisms or limited access to fluids, allowing the dehydration to progress unchecked over days. Panel A: HHS pathophysiology showing sufficient insulin to prevent ketosis but not hyperglycemia, resulting in extreme glucose elevation (greater than 600 mg/dL), massive osmotic diuresis, and hyperosmolarity (greater than 320 mOsm/kg) with neurologic manifestations. Panel B: Side-by-side comparison table of HHS versus DKA showing typical diabetes type (T2 vs T1), glucose levels, osmolality, ketone presence, pH, dehydration severity, mental status changes, and mortality rates (10-20% HHS vs 1-5% DKA). Panel C: HHS clinical features showing profound dehydration (often 8-12 liter deficit), altered mental status correlating with osmolality, focal neurologic signs potentially mimicking stroke, seizures, and absence of Kussmaul breathing (no significant acidosis). Panel D: HHS precipitants showing infection (pneumonia, UTI), medications (diuretics, steroids), non-compliance or undiagnosed diabetes, other illness (MI, stroke), and elderly or nursing home patients with limited fluid access. --- ### X. Chronic Complications - Pathophysiology Preview While the acute metabolic complications of diabetes are immediately life-threatening, it is the chronic complications that account for the majority of the long-term morbidity, mortality, and healthcare costs associated with diabetes mellitus. Chronic hyperglycemia damages tissues through several interconnected biochemical pathways, producing both microvascular and macrovascular disease. Understanding these mechanisms provides the rationale for aggressive glycemic control and the concept of glycemic memory. Chronic hyperglycemia causes tissue damage through at least five major biochemical pathways, all of which are activated when intracellular glucose concentrations exceed normal levels. The polyol pathway converts excess glucose to sorbitol via the enzyme aldose reductase, and sorbitol is subsequently converted to fructose. Sorbitol accumulation depletes NADPH (needed by aldose reductase as a cofactor), reduces glutathione regeneration, and causes osmotic damage, particularly in tissues that do not require insulin for glucose uptake such as the lens, peripheral nerves, and kidney. The formation of advanced glycation end-products (AGEs) occurs when glucose non-enzymatically glycates proteins, lipids, and nucleic acids; AGEs accumulate over time, cross-link structural proteins, activate the receptor for AGEs (RAGE) on endothelial cells and macrophages, and promote inflammation and oxidative stress. Activation of protein kinase C (PKC), particularly the beta isoform, by diacylglycerol produced from excess glucose causes vascular dysfunction through altered blood flow, increased vascular permeability, and extracellular matrix production. The hexosamine pathway diverts excess fructose-6-phosphate into the production of UDP-N-acetylglucosamine, which modifies proteins through O-GlcNAc modification, altering gene expression and contributing to insulin resistance. Oxidative stress from increased mitochondrial production of reactive oxygen species (ROS) represents a unifying mechanism that links the other pathways, as excess superoxide generation drives glucose into these alternative damaging pathways. Microvascular complications affect the small blood vessels and are relatively specific to diabetes. Diabetic retinopathy involves damage to retinal capillaries, leading to microaneurysms, hemorrhages, exudates, neovascularization, and ultimately vision loss; it is the leading cause of blindness in working-age adults. Diabetic nephropathy affects glomerular capillaries, progressing from hyperfiltration to microalbuminuria, overt proteinuria, and ultimately end-stage renal disease; it is the leading cause of renal failure requiring dialysis. Diabetic neuropathy results from damage to the vasa nervorum (the small blood vessels supplying peripheral nerves) as well as direct metabolic injury to nerve fibers, producing sensory loss, pain, and autonomic dysfunction. Macrovascular complications involve accelerated atherosclerosis in large and medium-sized arteries and are the leading cause of death in diabetic patients. Coronary artery disease is accelerated in diabetes, with diabetic patients having a 2-4 times increased risk of myocardial infarction and cardiovascular death compared to non-diabetic individuals. Cerebrovascular disease manifests as increased stroke risk. Peripheral artery disease causes claudication and, in severe cases, critical limb ischemia and gangrene, which combined with neuropathy and impaired wound healing, accounts for the high rate of lower extremity amputations in diabetic patients. The concept of glycemic memory, also known as metabolic memory or legacy effect, has emerged as a critical principle in diabetes management. This concept holds that periods of past hyperglycemia continue to influence the risk of complications even after glucose control is subsequently improved. The landmark evidence comes from the Diabetes Control and Complications Trial (DCCT) and its long-term follow-up study, the Epidemiology of Diabetes Interventions and Complications (EDIC) trial, which demonstrated that patients originally randomized to intensive glycemic control continued to have lower rates of microvascular and macrovascular complications years after the glycemic differences between the two treatment groups had converged. The implication is that early intensive glycemic control provides a lasting protective benefit. The mechanisms underlying glycemic memory are thought to involve epigenetic changes, including DNA methylation and histone modifications induced by hyperglycemia that persistently alter gene expression, as well as the accumulation of AGEs and persistent oxidative stress that continue to drive vascular damage even after normalization of glucose. Panel A: Hyperglycemia tissue damage pathways showing polyol pathway (glucose to sorbitol to fructose via aldose reductase), advanced glycation end-product (AGE) formation, protein kinase C (PKC) activation causing vascular dysfunction, hexosamine pathway, and oxidative stress with increased reactive oxygen species. Panel B: Microvascular complications showing retinopathy (retinal capillary damage), nephropathy (glomerular capillary damage), and neuropathy (vasa nervorum damage) as the classic triad of small vessel disease. Panel C: Macrovascular complications showing accelerated atherosclerosis causing coronary artery disease, cerebrovascular disease (stroke), and peripheral artery disease (claudication, gangrene) with 2-4 times increased cardiovascular risk. Panel D: Glycemic memory concept showing past hyperglycemia affecting future outcomes (DCCT/EDIC studies), early intensive control providing lasting benefit, and mechanisms including epigenetic changes and persistent AGE and ROS damage even after glucose normalization. --- ## Summary - Type 1 DM: Autoimmune β cell destruction; absolute insulin deficiency; HLA-associated - Type 2 DM: Insulin resistance + progressive β cell dysfunction; obesity-related - Insulin action: Receptor tyrosine kinase → IRS → PI3K → Akt → GLUT4 translocation - Insulin deficiency effects: Hyperglycemia, lipolysis, proteolysis, ketogenesis - DKA: Absolute insulin deficiency; ketoacidosis; anion gap metabolic acidosis - HHS: Relative insulin deficiency; extreme hyperglycemia; hyperosmolarity; minimal ketosis - Chronic complications: Polyol pathway, AGEs, PKC, oxidative stress → micro/macrovascular --- ## Key Terms | Term | Definition | |------|------------| | Type 1 diabetes | Autoimmune destruction of β cells; absolute insulin deficiency | | Type 2 diabetes | Insulin resistance with progressive β cell failure | | Insulin resistance | Decreased tissue response to insulin action | | GLUT4 | Insulin-responsive glucose transporter in muscle/adipose | | Diabetic ketoacidosis (DKA) | Hyperglycemia with ketoacidosis; insulin deficiency | | Hyperosmolar hyperglycemic state (HHS) | Severe hyperglycemia with hyperosmolarity; minimal ketosis | | HbA1c | Glycated hemoglobin; reflects average glucose over 2-3 months | | Incretins | GLP-1 and GIP; potentiate glucose-stimulated insulin secretion | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*